(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...

Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

Women who complain of bladder pain and urinary urgency and frequency wait years to receive the label of interstitial cystitis (IC), an "orphan disease" which has no known cause or cure. The current ...

ESMO 2022 CABASTY randomized phase III trial, older patients with mCRPC, results of CABASTY, ECOG performance status, Grade ≥3 neutropenia and/or neutropenic complications, Grade ≥3 adverse events, ...

Yohann Loriot’s presentation at EAU 2025 highlighted the potential of combining systemic and intravesical therapies for high-risk non-muscle invasive bladder cancer (HR-NMIBC). While BCG remains the ...

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Looking for the latest abstracts on prostate cancer treatment and research? We've got you covered and then some.

Siddharth Marthi presented the results of an institution-wide prostate cancer screening initiative at Grady Memorial Hospital, a safety-net hospital serving a high-risk, predominantly Black patient ...

ASCO 2025 HIF-2α targeting as a new frontier in renal cell cancer (RCC) therapy, Von Hippel-Lindau (VHL) gene mutation, LITESPARK-005, metastatic clear cell RCC. belzutifan.